Tag Archives: conflicts of interest

Say what? Psychiatrist Charles Nemeroff who failed to report $1.2 mil in Pharma deals lands psych chairmanship at University

Last year Nemeroff, as chair of the Department of Psychiatry at Emory University, was the intense focus of an investigation by Sen. Charles Grassley, R-Iowa, who said he was concerned about the money the psychiatrist received from drug companies while conducting supposedly unbiased research for the National Institutes of Health on drugs made by the companies he was receiving money from.

Psychiatrist exposed in Grassley investigation resigns after failing to report hundreds of thousands in Pharma funds

Charles Nemeroff, who failed to disclose to Emory University approximately $800,000 in payments he received from drug maker GlaxoSmithKline (GSK) while he was the principal investigator (PI) on a multi-million dollar grant from the NIH to study five GSK antidepressants, is leaving the university.

National Alliance on Mental Illness (NAMI) – A Pharma front group

The Citizens Commission on Human Rights (CCHR) states it is no wonder that the National Alliance on Mental Illness (NAMI), a group that claims to be an advocacy organization for people with “mental illness,” opposed the black box warnings on antidepressants causing suicide for under 18 year olds in 2004, and black box warnings on ADHD drugs causing heart attack, stroke and sudden death in children in 2006, when you look at their biggest source of funding: Pharma.

Shrinks for sale: Psychiatrist makes $22,500 in 3 months doing “educational” drug speeches for Eli Lilly

Lilly last month disclosed its $22 million in payments in the first quarter of this year to the 3,400 doctors who are called the Lilly faculty. The company paid a $1.4 billion penalty as part of its January settlement with the government. That amount was dwarfed by Pfizer’s $2.3 billion settlement on Sept. 2 for similar violations, which also requires disclosing physician speaking fees. Both cases centered on company actions that illegally promoted drugs for “off-label” uses, those not approved by federal officials.

In the wake of U.S. Senator Charles Grassley investigations, Medical Editors Push for Ghostwriting Crackdown

In light of recently released evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.